FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Supriya Lifescience IPO is a book built issue of Rs 700.00 crores. The issue is a combination of fresh issue of Rs 200.00 crores and offer for sale of Rs 500.00 crores.
Supriya Lifescience IPO bidding started from December 16, 2021 and ended on December 20, 2021. The allotment for Supriya Lifescience IPO was finalized on Thursday, December 23, 2021. The shares got listed on BSE, NSE on December 28, 2021.
Supriya Lifescience IPO price band is set at ₹265 to ₹274 per share. The minimum lot size for an application is 54 Shares. The minimum amount of investment required by retail investors is ₹14,796.
Axis Capital Limited and ICICI Securities Limited are the book running lead managers of the Supriya Lifescience IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Supriya Lifescience IPO RHP for detailed information.
IPO Date | December 16, 2021 to December 20, 2021 |
Listing Date | December 28, 2021 |
Face Value | ₹2 per share |
Price Band | ₹265 to ₹274 per share |
Lot Size | 54 Shares |
Total Issue Size | [.] shares (aggregating up to ₹700.00 Cr) |
Fresh Issue | [.] shares (aggregating up to ₹200.00 Cr) |
Offer for Sale | [.] shares of ₹2 (aggregating up to ₹500.00 Cr) |
Issue Type | Book Built Issue IPO |
Listing At | BSE, NSE |
Share holding pre issue | 73,183,530 |
Share holding post issue | 25,547,445 |
Supriya Lifescience IPO offers 14,528,299 shares. 7,924,527 (54.55%) to QIB, 3,962,263 (27.27%) to NII, 2,641,509 (18.18%) to RII. 48,916 RIIs will receive minimum 54 shares and (sNII) and (bNII) will receive minimum 756 shares. (in case of oversubscription)
Investor Category | Shares Offered | Maximum Allottees |
---|---|---|
Anchor Investor Shares Offered | - | NA |
QIB Shares Offered | 7,924,527 (54.55%) | NA |
NII (HNI) Shares Offered | 3,962,263 (27.27%) | |
Retail Shares Offered | 2,641,509 (18.18%) | 48,916 |
Total Shares Offered | 14,528,299 (100%) |
Supriya Lifescience IPO opens on December 16, 2021, and closes on December 20, 2021.
IPO Open Date | Thursday, December 16, 2021 |
IPO Close Date | Monday, December 20, 2021 |
Basis of Allotment | Thursday, December 23, 2021 |
Initiation of Refunds | Friday, December 24, 2021 |
Credit of Shares to Demat | Monday, December 27, 2021 |
Listing Date | Tuesday, December 28, 2021 |
Cut-off time for UPI mandate confirmation | 5 PM on December 20, 2021 |
Investors can bid for a minimum of 54 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
Application | Lots | Shares | Amount |
---|---|---|---|
Retail (Min) | 1 | 54 | ₹14,796 |
Retail (Max) | 13 | 702 | ₹192,348 |
Lot Size Calculator |
Satish Waman Wagh is the company promoter.
Share Holding Pre Issue | 99.98% |
Share Holding Post Issue | 68.24% |
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company has been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India between Fiscal 2017 and 2021. The company is also one of the largest exporters of Salbutamol Sulphate from India in FY 2021 in terms of volume.
In Fiscal 2021, the company's products were exported to 86 countries to 1,296 customers including 346 distributors. The company has API business in Europe, Latin America, Asia, and North America.
Supriya Lifescience has a modern manufacturing facility in Maharashtra spread across 23,806 sq. mts, having a reactor capacity of 547 KL/ day including 7 clean rooms. The company has also acquired a plot of land, admeasuring 12,551 sq. mt, near the present manufacturing facility, to expand its manufacturing infrastructure. The company's manufacturing facility has received approvals from USFDA, EDQM TGA-Australia, KFDA-Korea, PMDA Japan, NMPA (previously known as SFDA)- China, Health Canada, in relation to API products being exported to the relevant jurisdictions by the company.
Particulars | For the year/period ended (₹ in Millions) | ||||
---|---|---|---|---|---|
30-Sep-21 | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | ||
Total Assets | 5,041.02 | 4,458.24 | 3,364.01 | 2,530.52 | |
Total Revenue | 2,300.61 | 3,962.21 | 3,227.13 | 2,858.62 | |
Profit After Tax | 659.59 | 1,238.28 | 733.74 | 394.24 |
[Dilip Davda] SLL has been making strides with higher top and bottom lines year after year and exporting over 75% of products to more than 86 countries. Based on financial parameters, the issue is attractively priced leaving something on the table across the board. The issue is worth considering for short to long term rewards. Read detail review...
The Supriya Lifescience IPO is subscribed 71.51 times on December 20, 2021 7:52:00 PM. The public issue subscribed 56.01 times in the retail category, 31.83 times in the QIB category, and 161.22 times in the NII category. Check Day by Day Subscription Details (Live Status)
Category | Subscription (times) |
---|---|
QIB | 31.83 |
NII | 161.22 |
Retail | 56.01 |
Total | 71.51 |
Listing Date | December 28, 2021 |
BSE Script Code | 543434 |
NSE Symbol | SUPRIYA |
ISIN | INE07RO01027 |
Final Issue Price | ₹274 per share |
Price Details |
---|
Final Issue Price |
Open |
Low |
High |
Last Trade |
BSE |
---|
₹274.00 |
₹425.00 |
₹383.15 |
₹425.00 |
₹390.35 |
NSE |
---|
₹274.00 |
₹421.00 |
₹383.20 |
₹421.00 |
₹390.85 |
Supriya Lifescience Limited
207/208, Udyog Bhavan,
Sonawala Road, Goregaon,
East, Mumbai – 400063, Maharashtra, India
Phone: +91-22-40332727
Email: cs@supriyalifescience.com
Website: https://supriyalifescience.com/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: supriyalife.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Supriya Lifescience IPO is a main-board IPO of [.] equity shares of the face value of ₹2 aggregating up to ₹700.00 Crores. The issue is priced at ₹265 to ₹274 per share. The minimum order quantity is 54 Shares.
The IPO opens on December 16, 2021, and closes on December 20, 2021.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Supriya Lifescience IPO using UPI as a payment gateway. Zerodha customers can apply in Supriya Lifescience IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Supriya Lifescience IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Supriya Lifescience IPO opens on December 16, 2021 and closes on December 20, 2021.
Supriya Lifescience IPO lot size is 54 Shares, and the minimum amount required is ₹14,796.
You can apply in Supriya Lifescience IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Supriya Lifescience IPO will be done on Thursday, December 23, 2021, and the allotted shares will be credited to your demat account by Monday, December 27, 2021. Check the Supriya Lifescience IPO allotment status.
Useful Articles
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
IPO Guru (6600+ Posts, 21900+ Likes)
Issue was on 20th Dec ... management was projecting 45+ profit for the quarter … in 10 days how can they lose so much money ... so clearly they lied to sell issue
today anchor lock in also over ... so they might be sellers